Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent.
The neuromuscular blocking effects of Org 9426, the 2-morpholino, 16-allyl-pyrrolidino derivative of the 3-desacetoxy analogue of vecuronium have been investigated in anaesthetized patients. Based on data from a pilot study, two doses, 250 and 500 micrograms kg-1 (estimated as the ED90 and 2 x ED90, respectively) were chosen. Org 9426 appeared to be six to eight times less potent than vecuronium and showed a faster rate of development of neuromuscular block, with good to excellent intubation conditions within 60 s after administration of a dose of 500 micrograms kg-1. The duration of action and the recovery index appeared to be similar to those of vecuronium. Side effects were not noted. Org 9426 may have advantages over existing non-depolarizing neuromuscular blocking agents with respect to rate of development of good intubating conditions, and is stable in aqueous solutions.
Wierda
J M
JM
Institute for Experimental Anaesthesiology, University of Groningen, The Netherlands.
de Wit
A P
AP
Kuizenga
K
K
Agoston
S
S
D000293:Adolescent; D000328:Adult; D000732:Androstanols / Q000008:administration & dosage / Q000494:pharmacology*; D000768:Anesthesia, General; D004341:Drug Evaluation; D006801:Humans; D007442:Intubation, Intratracheal; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000077123:Rocuronium; D013997:Time Factors
D000732:Androstanols; D009466:Neuromuscular Blocking Agents; D000077123:Rocuronium